We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+8.11%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.6B
AUM Growth
+$562M
(+28%)
Cap. Flow
+$523M
Cap. Flow
% of AUM
20.1%
Top 10 Holdings %
Top 10 Hldgs %
52.45%
Holding
38
New
6
Increased
14
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$62.7M |
| 2 |
Viatris
VTRS
|
+$49M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$45.5M |
| 4 |
Perrigo
PRGO
|
+$40.5M |
| 5 |
Nektar Therapeutics
NKTR
|
+$38.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$67.5M |
| 3 |
Tenet Healthcare
THC
|
+$62.2M |
| 4 |
GSK
GSK
|
+$58.6M |
| 5 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$49.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $271M | 10.44% |
+1,000,000
| New | +$270M |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $168M | 6.45% |
1,005,000
+155,000
| +18% | +$24.9M |
|
3
HCA Healthcare
HCA
$88.4B
| $139M | 5.33% |
1,350,000
+100,000
| +8% | +$10.1M |
|
4
Biogen
BIIB
$30.9B
| $131M | 5.03% |
450,000
-65,000
| -13% | -$18.3M |
|
|
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
| $124M | 4.77% |
2,458,100
| – | – |
|
|
TSRO
6
DELISTED
TESARO, Inc.
TSRO
| $111M | 4.28% |
2,500,000
+775,000
| +45% | +$37.6M |
|
|
7
CALL
Bristol-Myers Squibb
BMY
$129B
| $111M | 4.26% |
+2,000,000
| New | +$108M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $110M | 4.22% |
650,000
-450,000
| -41% | -$72.6M |
|
9
Universal Health Services
UHS
$10.2B
| $100M | 3.86% |
900,000
+120,000
| +15% | +$14.1M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $99.4M | 3.83% |
2,200,000
+1,000,000
| +83% | +$45.5M |
|
|
11
Nektar Therapeutics
NKTR
$2.39B
| $97.7M | 3.76% |
133,333
+33,333
| +33% | +$38.4M |
|
|
12
Viatris
VTRS
$20.8B
| $90.3M | 3.48% |
2,500,000
+1,250,000
| +100% | +$49M |
|
|
CELG
13
CALL
DELISTED
Celgene Corp
CELG
| $79.4M | 3.06% |
+1,000,000
| New | +$83M |
|
|
14
Tenet Healthcare
THC
$22.2B
| $75.5M | 2.91% |
2,250,000
-2,000,000
| -47% | -$62.2M |
|
|
MDCO
15
DELISTED
Medicines Co
MDCO
| $73.4M | 2.82% |
2,000,000
| – | – |
|
|
EVHC
16
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $72.6M | 2.79% |
1,650,000
-1,200,000
| -42% | -$49.3M |
|
|
17
Perrigo
PRGO
$1.44B
| $67.4M | 2.59% |
925,000
+525,000
| +131% | +$40.5M |
|
|
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
| $62.5M | 2.41% |
1,200,000
| – | – |
|
|
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $62.5M | 2.4% |
3,055,000
+2,919,700
| +2,158% | +$62.7M |
|
20
Atara Biotherapeutics
ATRA
$72.6M
| $59.5M | 2.29% |
64,800
+132
| +0.2% | +$142K |
|
21
Brookdale Senior Living
BKD
$3.55B
| $59.1M | 2.27% |
6,500,000
| – | – |
|
22
Myriad Genetics
MYGN
$476M
| $56.1M | 2.16% |
1,500,000
| – | – |
|
|
CSII
23
DELISTED
Cardiovascular Systems, Inc.
CSII
| $53.3M | 2.05% |
1,647,677
+411,317
| +33% | +$11.3M |
|
|
ELGX
24
DELISTED
Endologix Inc
ELGX
| $52.6M | 2.03% |
930,000
| – | – |
|
|
AMAG
25
DELISTED
AMAG Pharmaceuticals
AMAG
| $51.7M | 1.99% |
2,650,000
| – | – |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Camber Capital Management held 38 positions worth $2.6B, up 28% from $2.04B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Camber Capital Management deployed $523M of net new capital in Q2 2018, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 1,900,000 shares worth $35.5M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 87% a quarter earlier.
On the sell side, the largest reduction was Shire pic, an estimated $72.6M trimmed.
- Camber Capital Management's largest Q2 2018 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 1,900,000 shares worth $35.5M.
- Camber Capital Management added most to Momenta Pharmaceuticals, Inc. in Q2 2018, an estimated $62.7M increase.
- Camber Capital Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $72.6M.
- Camber Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $67.5M.
- Camber Capital Management's ten largest holdings make up 52% of its $2.6B portfolio in Q2 2018.
- Camber Capital Management opened 6 new positions and closed 5 in Q2 2018.
- Camber Capital Management's portfolio value rose 28% quarter-over-quarter to $2.6B.
Based on Camber Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.